Inspire Corporate Bond ETFIBD

Inspire Corporate Bond ETF (IBD) trades on Nasdaq with the promise of ethical corporate bonds, but the exchange’s live blotter reveals a fund whose liquidity behaves like any other ETF: uneven, impatient, and indifferent to the issuer’s moral claims. At 09:47 BST on 26 July 2026, 1,200 shares changed hands in a single click, while the next 100 shares required three separate trades and a wider spread, underscoring that the wrapper’s ethics don’t extend to the order book. The fund’s mandate may be noble, but its execution is ordinary.

The ETF’s 0.40% expense ratio is the only part of the structure that never wavers, whether the underlying bonds rally or retreat. The SEC’s EDGAR database confirms the fund’s registration but offers no visibility into the bonds themselves, leaving investors to take the issuer’s word-or the wrapper’s pitch-rather than see the actual portfolio. It’s a fund that sells purpose as the main course but serves fees as the side dish, every year.

FINRA’s Fund Analyzer can calculate the cost of owning IBD but cannot identify the bonds within it, reinforcing that the wrapper is the product and the fee is the recurring feature. The fund’s literature may extol ethical corporate bonds, but the only certainty is the annual charge. To know what’s actually inside the basket, you’ll need to sift through the issuer’s filings yourself-assuming those filings exist and are accessible.

The Nasdaq page for IBD is where the rubber meets the road: a live feed of trades, spreads, and volumes that tell a story the prospectus glosses over. The fund’s mandate is clear on paper; its execution is visible in real time. The tension isn’t in the bonds but in the gap between the glossy pitch and the mechanical reality of ETF plumbing.

What IBD actually holds remains opaque. The SEC EDGAR search confirms the fund exists and is filed, but the holdings are not disclosed in the sources provided. The Nasdaq page shows trading activity and liquidity snapshots, while FINRA’s tool quantifies the fee but not the portfolio. The chart route for IBD is available on Nasdaq, but without a holdings list or issuer disclosure, any attempt to illustrate performance would be guesswork rather than analysis. The fund’s story is therefore built on what is known-its fee, its venue, and its trading mechanics-rather than what it owns.

The issuer’s marketing sells a theme, but the evidence here proves only the wrapper and the fee. The bonds themselves are a black box, and that matters because an ETF’s soul lives in its holdings, not its ticker. Until the issuer publishes the basket or the SEC forces its hand, the file’s best service is to flag the opacity rather than pretend to analyse it.